Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. David Cosgrove

David Peter Cosgrove, M.B.B.Ch.

Male  | Languages: English, German

Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map


Anal Cancer, Bile Duct Cancer, Cancer of Unknown Primary, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology , Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Stomach Cancer

Research Interests

Gastrointestinal malignancies; Hepatocellular carcinoma; Biliary tract malignancies, as well as carcinoma of unknown primary site


Dr. Cosgrove aims to identify molecular biomarkers in cancer cells that can differentiate them from normal cells. These differences at the genetic and molecular level should allow us to develop drugs that will target only the cancer cells, and have minimal side effects on the patients normal cells. He is working closely with the gastrointestinal malignancies group to bring new drugs and combinations into clinical practice. The ultimate goal is to identify the best drug, or combination of drugs, for individual patients based upon their tumors genetic makeup. The same approach should also allow us to identify drugs that will not be effective against particular tumors, so ineffective therapy can be avoided. more

    Additional Information

  • Education +


    • Faculty of Medicine National University of Ireland / MBBCh (2000)


    • Connolly Memorial Hospital / Internal Medicine (2002)
    • Johns Hopkins University School of Medicine / Internal Medicine (2006)


    • Johns Hopkins University School of Medicine / Medical Oncology (2009)


    • American Board of Internal Medicine / Internal Medicine (2007)
    • American Board of Internal Medicine / Medical Oncology (2008)
  • Research & Publications +

    Clinical Trial Keywords: Phase I, gastrointestinal malignancies,hepatocellular carcinoma and biliary tract malignancies,carcinoma of unknown primary site.

    Selected Publications

    Research Summary

    Dr. Cosgroves research is focused on molecular changes in tumor cells, specifically within proliferation pathways such as MAPK and PISK/AKT. He is developing agents to target these pathways, and biomarkers to identify patients most likely to benefit from such agents.

    Peer Reviewed Articles

    1. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835-40. PMCID: 2636736.

    2. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010;29(16):2337-45. PMCID: 3042798.

    3. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011;15(11):2089-97. PMCID: Not supported through NIH funds.

    4. Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther. 2011;11(3):358-67. PMCID: 3047087.

    5. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011;108(43):17773-8. PMCID: 3203756.

    6. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960-7. PMCID: Not supported through NIH funds.

    7. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA, Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69(2):415-24. PMCID: 3265723.

    Book Chapters

    1. Cosgrove D, Mouden M, Wise R. Chronic Obstructive Pulmonary Disease. In: Nilsson P, editor. Osler Handbook of Clinical Medicine, 2nd Edition. Philadelphia: Elsevier; 2006.

    2. Cosgrove D, Donehower R. Adenocarcinoma of Unknown Primary [database on the Internet]. BMJ Group 2010 [cited 07/2010].

    3. Cosgrove D, Park BH, Vogelstein B. Tumor Suppressor Genes. In: Waun Ki Hong, editor. Holland-Frei Cancer Medicine. Shelton: BC Decker/ American Association for Cancer Research; 2010. p. 86-102.

    1. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):733-40. PMCID: 2831175.

    2. Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15(3):410-5.

    3. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16(4):874-81. PMCID: Not funded through NIH support.

  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile